妇科肿瘤学家诊疗对原发性卵巢癌生存的影响:一项基于人群的研究
该研究利用全省行政数据纳入2007至2018年确诊的10,086例非黏液性上皮性卵巢癌患者,分析妇科肿瘤学家评估及手术医生类型对生存的影响。结果显示,首次治疗前未接受妇科肿瘤学家评估者全因死亡风险升高(HR 1.61;95%CI 1.46-1.79),由非妇科肿瘤学家实施手术者全因死亡风险亦升高(HR 2.03;95%CI 1.80-2.30)。作者倡导所有新发或疑似卵巢癌患者在开始初始治疗前接受妇科肿瘤学家评估。
要点
- 2007至2018-19年,妇科肿瘤学家评估率从79%升至87%(p≤0.001)。
- 同期由妇科肿瘤学家实施手术的比例从69%升至88%(p≤0.001)。
- 首次治疗前未接受妇科肿瘤学家评估者全因死亡风险升高(HR 1.61;95%CI 1.46-1.79)。
核心结论
- 首次治疗前接受妇科肿瘤学家评估与更好的生存相关,如同由妇科肿瘤学家实施原发卵巢癌手术一样。
- 作者倡导所有新发或疑似卵巢癌患者在开始初始治疗前接受妇科肿瘤学家评估。
研究设计与样本
- 基于全省行政数据的基于人群的研究,纳入2007至2018年确诊的非黏液性上皮性卵巢癌患者共10,086例。
- 采用多变量Cox比例风险回归模型评估首次治疗前妇科肿瘤学家评估或由非妇科肿瘤学家实施手术对死亡率的影响。
主要发现
- 研究期间妇科肿瘤学家评估率从2007年的79%升至2018-19年的87%(p≤0.001),增幅8%。
- 由妇科肿瘤学家实施手术的比例从2007年的69%升至2018-19年的88%(p≤0.001),增幅19%。
- 首次治疗前未接受妇科肿瘤学家评估的患者全因死亡风险升高(HR 1.61;95%CI 1.46-1.79)。
- 由非妇科肿瘤学家实施卵巢癌手术的患者全因死亡风险升高(HR 2.03;95%CI 1.80-2.30)。
临床怎么用
- 作者倡导所有新发或疑似卵巢癌患者在开始初始治疗前接受妇科肿瘤学家评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Timely treatment of epithelial ovarian cancer (EOC) by gynecologic oncologists (GOs) with a combination of surgery and/or chemotherapy has been advocated. Nonetheless, some patients are not assessed by GOs prior to starting their treatment or have surgery by non-GOs. This study aims to determine trends over time in non-mucinous EOC care and to evaluate the impact of care on survival. METHODS: Using province-wide administrative data, patients diagnosed with non-mucinous EOC between 2007 and 2018 were identified. Multivariate Cox proportional hazards regression models were used to evaluate the impact of GO assessment prior to initiating treatment or having surgery done by a non-GO on mortality. RESULTS: A total of 10,086 EOC patients were included between 2007 and 2018. During the study period, there was an 8% increase in GO assessment (79% in 2007 to 87% in 2018-19, p ≤ 0.001) and a 19% increase in surgeries performed by GOs (69% in 2007 to 88% in 2018-19, p ≤ 0.001). On multivariate analysis, there was an increased hazard of all-cause mortality for patients not assessed by GOs before first treatment (Hazard ratio (HR): 1.61; 95% CI 1.46-1.79). There was an increased hazard of all-cause mortality if ovarian cancer surgery was performed by non-GOs (HR 2.03; 95% CI 1.80-2.30). CONCLUSION: Assessment by GO before starting initial treatment is associated with improved survival in women with non-mucinous EOC as the type of surgeon performing primary ovarian cancer surgery. Assessment by GO for all patients with new or suspected ovarian cancer diagnosis before initiation of primary treatment should be advocated.
引用
- Bouchard-Fortier G, Gien LT, Sutradhar R, et al. Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study. Gynecol Oncol. 2022. PMID: 35063277. doi:10.1016/j.ygyno.2022.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。